Scaffolding to build a rational vaccine design strategy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 42, 2010, Pages 17859-17860

  Burton, Dennis R ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; LIVE VACCINE; MOLECULAR SCAFFOLD; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY 2F5; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE;

ANTIBODY RESPONSE; DRUG DESIGN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; NONHUMAN; NOTE; PRIORITY JOURNAL; VIRUS ATTENUATION;

ANIMALS; BACTERIAL VACCINES; DRUG DESIGN; GUINEA PIGS; MICE; VIRAL VACCINES;

EID: 78149277602     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1012923107     Document Type: Note

References (21)

1. Ofek G, et al. (2010) Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci USA 107:17880-17887.
2. Rinaudo CD, Telford JL, Rappuoli R, Seib KL (2009) Vaccinology in the genome era. J Clin Invest 119:2515-2525.
3. Burton DR (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2:706-713.
4. Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28:413-444.
5. Muster T, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67:6642-6647.
6. Hessell AJ, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302-1313.
7. Zwick MB, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75:10892-10905.
8. Ofek G, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its epitope. J Virol 78:10724-10737.
9. Pai EF, Klein MH, Chong P, Pedyczak A (2000) Fab′-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5. World Intellectual Property Organization. Patent WO-00/61618.
10. Julien JP, Bryson S, Nieva JL, Pai EF (2008) Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: Epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol 384:377-392.
11. Zwick MB, et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 78:3155-3161.
12. Julien JP, et al. (2010) Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol 84:4136-4147.
13. Ofek G, et al. (2010) Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 84:2955-2962.
14. Haynes BF, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
15. Scherer EM, Zwick MB, Teyton L, Burton DR (2007) Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21:2131-2139. (Pubitemid 350287210)
16. Apellaniz B, et al. (2010) Confocal microscopy of giant vesicles supports the absence of HIV-1 neutralizing 2F5 antibody reactivity to plasma membrane phospholipids. FEBS Lett 584:1591-1596.
17. Matyas GR, Beck Z, Karasavvas N, Alving CR (2009) Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 1788:660-665.
18. Song L, et al. (2009) Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci USA 106:9057-9062.
19. Correia BE, et al. (2010) Computational design of epitope- scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18:1116-1126.
20. Stiegler G, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17:1757-1765. (Pubitemid 34114213)
21. Cardoso RM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.